New GlycoMark Blood Test To Detect Underlying Treatment Effects

Armen Hareyan's picture

Blood Test

Research underscored the utility of the GlycoMark 1,5-anhydroglucitol (1,5-AG) blood test to detect underlying treatment effects in patients with diabetes.


These treatment effects were not readily revealed by the gold standard hemoglobin A1C diabetes test.

Although the A1C test provides important information about how blood glucose has behaved over the preceding two or three months, the test does not provide specific information on blood glucose performed right after meals. This is a critical measurement because a growing body of evidence suggests that controlling after-meal glucose levels plays a significant role in achieving optimal glycemic control and reducing the burden of cardiovascular complications, the leading cause of death in patients with diabetes.

In contrast, GlycoMark provides a specific measure of average after-meal glucose levels over a period of one to two weeks with one single blood test -- revealing potentially abnormal after-meal glucose elevations that would otherwise go undetected by the A1C test. In a recent study published in the American Diabetes Association Diabetes Care journal (Dungan et al. Diabetes Care 2006; 29 (6): 1214-1219), it was shown that the GlycoMark 1,5-AG test reflected after-meal glucose levels more robustly than the A1C test. The study also showed that GlycoMark was able to reveal dramatically different after-meal glucose levels in patients with similar A1C levels.

In studies presented at the 67th Annual Scientific Sessions of the American Diabetes Association and other recent meetings, the use of GlycoMark as a specific measure of after-meal glucose levels was confirmed. The studies also show that GlycoMark is particularly valuable in detecting underlying treatment effects on after-meal glucose levels. These findings have important implications for patient care and pharmaceutical research as the reduction of after-meal glucose rises is a key objective of diabetes drug therapy.